Importance Myelofibrosis is a hematologic malignancy characterized by splenomegaly and
debilitating symptoms. Thrombocytopenia is a poor prognostic feature and limits use of …

Myelofibrosis (MF) is a BCR-ABL1− myeloproliferative neoplasm that arises from
hematopoietic stem and progenitor cells frequently harboring a somatic driver mutation in 1 …

Background Available therapies for myelofibrosis can exacerbate cytopenias and are not
indicated for patients with severe thrombocytopenia. Pacritinib, which inhibits both JAK2 and …

Myelofibrosis (MF) is a clonal hematopoietic stem cell neoplasm, characterized by
pathologic myeloproliferation associated with inflammatory and pro-angiogenic cytokine …

Myelofibrosis (MF) can present with symptomatic splenomegaly and/or cytopenias including
thrombocytopenia. Disease-related thrombocytopenia is a poor prognostic factor with a …

Abstract Severe thrombocytopenia (platelets< 50× 109/L) is associated with very poor
outcome of patients with myelofibrosis (MF). As patients with primary myelofibrosis (PMF) …

Background This study analyses treatment patterns, health care resource utilization (HCRU),
and costs in patients with myelofibrosis (MF) and a subgroup treated with ruxolitinib (RUX) …

Myelofibrosis (MF) is a clonal hematopoietic stem cell neoplasm characterized by
constitutional symptoms, splenomegaly, and risks of marrow failure or leukemic …

Introduction: Treatment with ruxolitinib, a selective JAK1/2 inhibitor, has significantly
improved the lives of patients with myelofibrosis. Unfortunately, this treatment is frequently …

‘JAK–ing’ up the treatment of primary myelofibrosis: buildin... : Current Opinion in
Hematology ‘JAK–ing’ up the treatment of primary myelofibrosis: building better …